EASTONBIOPHARMACEUTICALS(SH:688513) Ge Long Hui A P P·2025-10-17 08:47Core Viewpoint - Yuan Dong Biotech (688513.SH) has received approval from the National Medical Products Administration for its drug, Elamomab Tablets, which is indicated for active rheumatoid arthritis and is classified as a Category B drug in the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog [1] Group 1 - The company’s wholly-owned subsidiary, Chengdu Shuo De Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Elamomab Tablets [1] - Elamomab, the active ingredient in the tablets, is specifically aimed at treating active rheumatoid arthritis [1] - The drug is included in the 2024 National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog as a Category B product [1]